Purchase Order HDTRA115P0034
- Not listed
- This is a $149,543.35 Firm Fixed Price contract awarded by the U.S. Army Medical Command (MEDCOM) to Biological Mimetics, Inc., a small business, under the Small Business Innovation Research (SBIR) program. The contract is for a Phase I SBIR project to develop a CRISPR-based diagnostic test for parasites. The contract has a period of performance through August 30, 2016. Biological Mimetics is a biotechnology firm that provides research, development, and testing services related to infectious...
- This is a $299,820.00 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Biological Mimetics, Inc. for a Phase I Small Business Innovation Research (SBIR) project to develop a CRISPR-based diagnostic test for parasites. The contract is not set aside. Biological Mimetics is a biotechnology firm that conducts research and development on infectious diseases, vaccines, diagnostics, and...
- This is a Phase II SBIR contract award to Biological Mimetics, Inc., a biotechnology firm in Frederick, Maryland, by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency. The $1,498,641 Firm Fixed Price contract is for the development of a CRISPR-based diagnostic test for parasites, with a completion date of September 14, 2028. The contract is set aside for small businesses under the SBIR program, which aims to stimulate technological innovation. Biological...
- <p>This is a Phase II Small Business Innovation Research (SBIR) contract awarded by the Defense Threat Reduction Agency (DTRA), a defense agency, to Biofactura Inc., a small business manufacturer, for the process development and manufacture of an antibody-based therapy against Marburgvirus. The contract is a Firm Fixed Price Definitive Contract with a ceiling value of $999,398.93 and a period of performance ending on September 14, 2022. The contract is set aside for small businesses.</p>
- This is a $5,057,523.60 definitive contract awarded by the Defense Threat Reduction Agency (DTRA) to Microbiotix, Inc., a clinical-stage biopharmaceutical company. The contract, which is not set-aside, supports the development of novel small molecule anti-infective drugs, with a focus on addressing unmet medical needs in infectious diseases. Microbiotix has received numerous federal contract and grant awards from agencies such as the National Institutes of Health (NIH) and the Department of...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Defense Health Agency (DHA) to Firebird Biomolecular Sciences LLC, a for-profit limited liability company, for the development of "Innovative DNA for Highly Multiplexed Molecular Diagnostics". The $249,956.88 firm-fixed-price contract has a period of performance ending on May 8, 2025. The contract supports research and development of novel molecular technologies to create a rapid, point-of-sampling...
- This firm-fixed-price SBIR Phase I contract was awarded by the Department of Health and Human Services' National Institute of Allergy and Infectious Diseases to HDT Bio Corp, a for-profit biopharmaceutical company. The $599,629 contract funds the "Rational Development of a Combination Nanoparticle Adjuvant for Influenza", which involves research and development of novel adjuvants and other medical countermeasures. HDT Bio Corp has previously served as a prime contractor on other HHS...
- This is a $225,000.00 Firm Fixed Price contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Technology Holding LLC, a small, for-profit limited liability company specializing in research and development services. The contract is part of DARPA's Small Business Innovation Research (SBIR) program and is for Phase I of an effort titled "AUTONOMOUS BIOMANUFACTORING AT REMOTE LOCATIONS". The contract has a total small business set-aside and supports the development of...
- <p>This is a firm fixed-price SBIR Phase I contract awarded by the Joint PEO Chemical and Biological Defense, a Defense agency, to Cygnos Biotech, LLC, a small business located in Miami, Florida. The contract, valued at $204,493.42, is for research to create a class of agnostic drugs that can assist in fighting off a broad spectrum of viral pathogens. The contract has an ultimate completion date of August 9, 2025.</p>
- <p>This is a $1,999,175.53 firm fixed-price Definitive Contract awarded by the Defense Health Agency (DHA), a defense agency, to Technovax Inc., a small disadvantaged business, under the SBIR (Small Business Innovation Research) Phase II program. The contract is for research and development work, with a period of performance ending on February 16, 2021. The contract was set aside for small businesses.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Defense Threat Reduction Agency (DTRA) to Biological Mimetics, Inc., a biotechnology firm that specializes in infectious disease research and vaccine development. The $149,992.18 firm-fixed-price contract is for the delivery of reports related to the SBIR Phase I research. Biological Mimetics has received prior federal grants and contracts to support its work on vaccine candidates against pathogens such as influenza, Staphylococcus aureus, and Porcine Circovirus Type 2. This SBIR Phase I contract represents additional funding for the company's research and development efforts, which leverage its expertise in areas like CRISPR-based diagnostics and immune refocusing technology to enhance vaccine effectiveness.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00001 | Other Administrative Action | $0 | 2/2/16 | |
| Not listed | Not listed | $150.0k | 9/24/15 |